Acasti Pharma (Acasti Pharma) 6-1 Month Momentum % : 37.80% (As of May. 24, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-24), Acasti Pharma's 6-1 Month Momentum % is 37.80%.

The industry rank for Acasti Pharma's 6-1 Month Momentum % or its related term are showing as below:

ACST's 6-1 Month Momentum % is ranked better than
77.97% of 1525 companies
in the Biotechnology industry
Industry Median: -4.76 vs ACST: 37.80

Competitive Comparison of Acasti Pharma's 6-1 Month Momentum %

For the Biotechnology subindustry, Acasti Pharma's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acasti Pharma's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acasti Pharma's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Acasti Pharma's 6-1 Month Momentum % falls into.

Acasti Pharma (NAS:ACST) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acasti Pharma (NAS:ACST) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Acasti Pharma 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acasti Pharma (Acasti Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (NAS:ACST) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

A1P0:Germany

Address

3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5

Website

https://www.acastipharma.com

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.

Executives

George Kottayil	director	49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren	director	282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru	director	11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds	director	545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar	officer: VP Program Management	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea	officer: VP Clinical Operations	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli	officer: Chief Executive Officer	206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald	officer: Chief Medical Officer	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby	director	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine	director
Rajitha Grace 2018 Irrevocable Trust	10 percent owner	40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer	10 percent owner	20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford	officer: CHIEF FINANCIAL OFFICER	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan	director	C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202